Piergiuseppe Colombo

Prof. Dr. Piergiuseppe Colombo

1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
Barbara MolonBarbara Molon
Barbara Molon
SUStefano Ugel
Stefano Ugel
FPFederica Del Pozzo
Federica Del Pozzo
CScristiana soldani
cristiana soldani
SZSerena Zilio
Serena Zilio
AVAntonella Viola
Antonella Viola
Tumor-promoted constraints negatively affect cytotoxic T lymphocyte (CTL) trafficking to the tumor core and, as a result, inhibit tumor killing. The production of reactive nitrogen species (RNS) within the tumor microenvironment has been reported in mouse and human cancers. We describe a novel RNS-dependent posttranslational modification of chemokines that has a profound impact on leukocyte recruitment to mouse and human tumors. Intratumoral RNS production induces CCL2 chemokine nitration and hinders T cell infiltration, resulting in the trapping of tumor-specific T cells in the stroma that surrounds cancer cells. Preconditioning of the tumor microenvironment with novel drugs that inhibit CCL2 modification facilitates CTL invasion of the tumor, suggesting that these drugs may be effective in cancer immunotherapy. Our results unveil an unexpected mechanism of tumor evasion and introduce new avenues for cancer immunotherapy.

1 February 2015 in Cell
Verified
Journal Article
Closed access
Eduardo BonavitaEduardo Bonavita
Eduardo Bonavita
SGStefania Gentile
Stefania Gentile
MRMarcello Rubino
Marcello Rubino
VMVirginia Maina
Virginia Maina
RPRoberto Papait
Roberto Papait
Alberto MantovaniAlberto Mantovani
Alberto Mantovani

1 July 2019 in Cell
Verified
Journal Article
Open access
APAndrea Ponzetta
Andrea Ponzetta
RCRoberta Carriero
Roberta Carriero
SCSilvia Carnevale
Silvia Carnevale
MBMarialuisa Barbagallo
Marialuisa Barbagallo
MMMartina Molgora
Martina Molgora
SJSebastien Jaillon
Sebastien Jaillon
Neutrophils are a component of the tumor microenvironment and have been predominantly associated with cancer progression. Using a genetic approach complemented by adoptive transfer, we found that neutrophils are essential for resistance against primary 3-methylcholantrene-induced carcinogenesis. Neutrophils were essential for the activation of an interferon-γ-dependent pathway of immune resistance, associated with polarization of a subset of CD4- CD8- unconventional αβ T cells (UTCαβ). Bulk and single-cell RNA sequencing (scRNA-seq) analyses unveiled the innate-like features and diversity of UTCαβ associated with neutrophil-dependent anti-sarcoma immunity. In selected human tumors, including undifferentiated pleomorphic sarcoma, CSF3R expression, a neutrophil signature and neutrophil infiltration were associated with a type 1 immune response and better clinical outcome. Thus, neutrophils driving UTCαβ polarization and type 1 immunity are essential for resistance against murine sarcomas and selected human tumors.

17 December 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MMMichela Masetti
Michela Masetti
RCRoberta Carriero
Roberta Carriero
FPFederica Portale
Federica Portale
GMGiulia Marelli
Giulia Marelli
NMNicolò Morina
Nicolò Morina
DMDiletta Di Mitri
Diletta Di Mitri
Tumor-associated macrophages (TAMs) are correlated with the progression of prostatic adenocarcinoma (PCa). The mechanistic basis of this correlation and therapeutic strategies to target TAMs in PCa remain poorly defined. Here, single-cell RNA sequencing was used to profile the transcriptional landscape of TAMs in human PCa, leading to identification of a subset of macrophages characterized by dysregulation in transcriptional pathways associated with lipid metabolism. This subset of TAMs correlates positively with PCa progression and shorter disease-free survival and is characterized by an accumulation of lipids that is dependent on Marco. Mechanistically, cancer cell–derived IL-1β enhances Marco expression on macrophages, and reciprocally, cancer cell migration is promoted by CCL6 released by lipid-loaded TAMs. Moreover, administration of a high-fat diet to tumor-bearing mice raises the abundance of lipid-loaded TAMs. Finally, targeting lipid accumulation by Marco blockade hinders tumor growth and invasiveness and improves the efficacy of chemotherapy in models of PCa, pointing to combinatorial strategies that may influence patient outcomes.

1 July 2018 in Journal of Urology
Verified
Journal Article
Closed access
Egesta LopciEgesta Lopci
Egesta Lopci
ASAlberto Saita
Alberto Saita
Massimo LazzeriMassimo Lazzeri
Massimo Lazzeri
GLGiovanni Lughezzani
Giovanni Lughezzani
PCPiergiuseppe Colombo
Piergiuseppe Colombo
PCPaolo Casale
Paolo Casale
68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography may represent the most promising imaging modality to identify and risk stratify prostate cancer in patients with contraindications to or negative multiparametric magnetic resonance imaging. In this prospective observational study we analyzed 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography in a select group of patients with persistently elevated prostate specific antigen and/or Prostate Health Index suspicious for prostate cancer, negative digital rectal examination and at least 1 negative biopsy. The cohort comprised men with equivocal multiparametric magnetic resonance imaging (Prostate Imaging-Reporting and Data System, version 2 score of 2 or less), or an absolute or relative contraindication to multiparametric magnetic resonance imaging. Sensitivity, specificity and CIs were calculated compared to histopathology findings. ROC analysis was applied to determine the optimal cutoff values of 68Ga labeled prostate specific membrane antigen uptake to identify clinically significant prostate cancer (Gleason score 7 or greater). A total of 45 patients with a median age of 64 years were referred for 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography between January and August 2017. The 25 patients (55.5%) considered to have positive positron emission tomography results underwent software assisted fusion biopsy. We determined the uptake values of regions of interest, including a median maximum standardized uptake value of 5.34 (range 2.25 to 30.41) and a maximum-to-background standardized uptake value ratio of 1.99 (range 1.06 to 14.42). Mean and median uptake values on 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography (ie the maximum standardized uptake value or the maximum-to-background standardized uptake value ratio) were significantly higher for Gleason score 7 lesions than for Gleason score 6 or benign lesions (p <0.001). On ROC analysis a maximum standardized uptake value of 5.4 and a maximum-to-background standardized uptake value ratio of 2 discriminated clinically relevant prostate cancer with 100% overall sensitivity in each case, and 76% and 88% specificity, respectively. Our findings support the use of 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography for primary detection of prostate cancer in a specific subset of men.

1 August 2006 in Toxicology
Verified
Journal Article
Closed access
Nicoletta GaglianoNicoletta Gagliano
Nicoletta Gagliano
IDIsabella Dalle Donne
Isabella Dalle Donne
CTCarlo Torri
Carlo Torri
Massimiliano MiglioriMassimiliano Migliori
Massimiliano Migliori
Fabio GrizziFabio Grizzi
Fabio Grizzi
MGMagda Gioia
Magda Gioia